Despite complete or near‐complete suppression of human immunodeficiency virus (HIV)
replication with combination antiretroviral therapy, both HIV and chronic …

Given the limitations of antiretroviral therapy and recent advances in our understanding of
HIV persistence during effective treatment, there is a growing recognition that a cure for HIV …

The possibility of HIV-1 eradication has been limited by the existence of latently infected
cellular reservoirs. Studies to examine control of HIV latency and potential reactivation have …

Chemokine (C–C motif) ligand 19 (CCL19) is a critical regulator of the induction of T cell
activation, immune tolerance, and inflammatory responses during continuous immune …

The latent reservoir for HIV-1 in resting memory CD4+ T cells is the major barrier to curing
HIV-1 infection. Studies of HIV-1 latency have focused on regulation of viral gene expression …

Effective antiretroviral therapy (ART) blunts viraemia, which enables HIV-1-infected
individuals to control infection and live long, productive lives. However, HIV-1 infection …

HIV persists in latently infected CD4+ T cells during antiretroviral therapy (ART). Immune
checkpoint molecules, including PD-1, are preferentially expressed at the surface of …

Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to
regimens that are both expensive and associated with toxic effects. A curative intervention …

Abstract Background Quiescent CD4+ T lymphocytes are highly refractory to HIV-1 infection
due to a block at reverse transcription. Results Examination of SAMHD1 expression in …

Treatment with antiretroviral therapy dramatically increases the survival of HIV-infected
individuals. However, treatment has to be continued for life because it does not lead to the …